vs
Side-by-side financial comparison of Mistras Group, Inc. (MG) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($196.9M vs $181.5M, roughly 1.1× Mistras Group, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $26.0M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs -0.8%).
Mistras Group, Inc. is a global provider of asset integrity and protection solutions, offering non-destructive testing, inspection, real-time monitoring, and engineering consulting services. Its key client segments include oil and gas, aerospace, power generation, and manufacturing industries, with operations spanning North America, Europe, and Asia-Pacific, helping clients enhance operational safety, extend asset lifespans, and minimize unplanned downtime.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
MG vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $181.5M | $196.9M |
| Net Profit | $3.8M | — |
| Gross Margin | 28.4% | 79.5% |
| Operating Margin | 7.0% | 1.2% |
| Net Margin | 2.1% | — |
| Revenue YoY | 5.1% | 5.1% |
| Net Profit YoY | -27.4% | — |
| EPS (diluted) | $0.12 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $181.5M | $196.9M | ||
| Q3 25 | $195.5M | $179.5M | ||
| Q2 25 | $185.4M | $181.1M | ||
| Q1 25 | $161.6M | $168.9M | ||
| Q4 24 | $172.7M | $187.3M | ||
| Q3 24 | $182.7M | $168.6M | ||
| Q2 24 | $189.8M | $178.0M | ||
| Q1 24 | $184.4M | $167.1M |
| Q4 25 | $3.8M | — | ||
| Q3 25 | $13.1M | $5.4M | ||
| Q2 25 | $3.0M | $-4.8M | ||
| Q1 25 | $-3.2M | $4.8M | ||
| Q4 24 | $5.2M | — | ||
| Q3 24 | $6.4M | $-143.5M | ||
| Q2 24 | $6.4M | $18.9M | ||
| Q1 24 | $995.0K | $9.0M |
| Q4 25 | 28.4% | 79.5% | ||
| Q3 25 | 29.8% | 80.9% | ||
| Q2 25 | 29.1% | 77.4% | ||
| Q1 25 | 25.3% | 79.7% | ||
| Q4 24 | 26.5% | 78.7% | ||
| Q3 24 | 26.8% | 76.9% | ||
| Q2 24 | 27.1% | 75.1% | ||
| Q1 24 | 25.0% | 71.6% |
| Q4 25 | 7.0% | 1.2% | ||
| Q3 25 | 10.4% | 3.5% | ||
| Q2 25 | 4.5% | 4.7% | ||
| Q1 25 | -0.6% | 1.2% | ||
| Q4 24 | 6.1% | 13.2% | ||
| Q3 24 | 6.5% | -82.8% | ||
| Q2 24 | 6.3% | 15.9% | ||
| Q1 24 | 3.0% | 7.9% |
| Q4 25 | 2.1% | — | ||
| Q3 25 | 6.7% | 3.0% | ||
| Q2 25 | 1.6% | -2.7% | ||
| Q1 25 | -2.0% | 2.8% | ||
| Q4 24 | 3.0% | — | ||
| Q3 24 | 3.5% | -85.1% | ||
| Q2 24 | 3.4% | 10.6% | ||
| Q1 24 | 0.5% | 5.4% |
| Q4 25 | $0.12 | $0.05 | ||
| Q3 25 | $0.41 | $0.12 | ||
| Q2 25 | $0.10 | $-0.11 | ||
| Q1 25 | $-0.10 | $0.10 | ||
| Q4 24 | $0.17 | $0.38 | ||
| Q3 24 | $0.20 | $-3.11 | ||
| Q2 24 | $0.20 | $0.39 | ||
| Q1 24 | $0.03 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $28.0M | $238.4M |
| Total DebtLower is stronger | $178.0M | $372.2M |
| Stockholders' EquityBook value | $235.1M | $693.1M |
| Total Assets | $578.8M | $1.3B |
| Debt / EquityLower = less leverage | 0.76× | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.0M | $238.4M | ||
| Q3 25 | $27.8M | $246.3M | ||
| Q2 25 | $20.0M | $445.9M | ||
| Q1 25 | $18.5M | $493.6M | ||
| Q4 24 | $18.3M | $484.6M | ||
| Q3 24 | $20.4M | $453.8M | ||
| Q2 24 | $17.2M | $404.2M | ||
| Q1 24 | $16.9M | $325.9M |
| Q4 25 | $178.0M | $372.2M | ||
| Q3 25 | $202.3M | $376.7M | ||
| Q2 25 | $189.4M | $580.5M | ||
| Q1 25 | $171.9M | $583.4M | ||
| Q4 24 | $169.6M | $585.3M | ||
| Q3 24 | $189.7M | — | ||
| Q2 24 | $199.7M | — | ||
| Q1 24 | $198.4M | — |
| Q4 25 | $235.1M | $693.1M | ||
| Q3 25 | $227.4M | $727.2M | ||
| Q2 25 | $215.8M | $757.8M | ||
| Q1 25 | $198.7M | $798.5M | ||
| Q4 24 | $198.6M | $778.3M | ||
| Q3 24 | $205.2M | $749.6M | ||
| Q2 24 | $193.2M | $879.3M | ||
| Q1 24 | $187.1M | $892.2M |
| Q4 25 | $578.8M | $1.3B | ||
| Q3 25 | $596.3M | $1.3B | ||
| Q2 25 | $571.0M | $1.5B | ||
| Q1 25 | $526.8M | $1.6B | ||
| Q4 24 | $523.0M | $1.6B | ||
| Q3 24 | $551.7M | $1.5B | ||
| Q2 24 | $548.1M | $1.6B | ||
| Q1 24 | $542.1M | $1.6B |
| Q4 25 | 0.76× | 0.54× | ||
| Q3 25 | 0.89× | 0.52× | ||
| Q2 25 | 0.88× | 0.77× | ||
| Q1 25 | 0.87× | 0.73× | ||
| Q4 24 | 0.85× | 0.75× | ||
| Q3 24 | 0.92× | — | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | 1.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.1M | $43.7M |
| Free Cash FlowOCF − Capex | $26.0M | $43.5M |
| FCF MarginFCF / Revenue | 14.3% | 22.1% |
| Capex IntensityCapex / Revenue | 3.4% | 0.1% |
| Cash ConversionOCF / Net Profit | 8.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | $8.3M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.1M | $43.7M | ||
| Q3 25 | $4.5M | $60.8M | ||
| Q2 25 | $-9.3M | $12.0M | ||
| Q1 25 | $5.6M | $35.5M | ||
| Q4 24 | $25.7M | $33.1M | ||
| Q3 24 | $19.4M | $53.9M | ||
| Q2 24 | $4.5M | $53.2M | ||
| Q1 24 | $604.0K | $49.1M |
| Q4 25 | $26.0M | $43.5M | ||
| Q3 25 | $-4.1M | $57.0M | ||
| Q2 25 | $-14.7M | $9.3M | ||
| Q1 25 | $1.1M | $26.9M | ||
| Q4 24 | $22.1M | $31.0M | ||
| Q3 24 | $14.6M | $49.8M | ||
| Q2 24 | $-284.0K | $51.6M | ||
| Q1 24 | $-4.2M | $46.3M |
| Q4 25 | 14.3% | 22.1% | ||
| Q3 25 | -2.1% | 31.7% | ||
| Q2 25 | -7.9% | 5.1% | ||
| Q1 25 | 0.7% | 15.9% | ||
| Q4 24 | 12.8% | 16.6% | ||
| Q3 24 | 8.0% | 29.6% | ||
| Q2 24 | -0.1% | 29.0% | ||
| Q1 24 | -2.3% | 27.7% |
| Q4 25 | 3.4% | 0.1% | ||
| Q3 25 | 4.4% | 2.2% | ||
| Q2 25 | 2.9% | 1.5% | ||
| Q1 25 | 2.8% | 5.1% | ||
| Q4 24 | 2.1% | 1.1% | ||
| Q3 24 | 2.6% | 2.4% | ||
| Q2 24 | 2.5% | 0.9% | ||
| Q1 24 | 2.6% | 1.7% |
| Q4 25 | 8.55× | — | ||
| Q3 25 | 0.34× | 11.20× | ||
| Q2 25 | -3.07× | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | 4.96× | — | ||
| Q3 24 | 3.02× | — | ||
| Q2 24 | 0.71× | 2.82× | ||
| Q1 24 | 0.61× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MG
Segment breakdown not available.
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
